X

You're leaving www.fatty15.com and being redirected to an external site.

If the site does not reload after 5 seconds please copy and paste this link. https://www.seraphinatherapeutics.com/yourhealth.html

Fatty15 is 3X better than omega-3. Read the science.

Patents held by Seraphina Therapeutics

fatty15

Seraphina Therapeutics has exclusive and global licensing rights from the U.S. Navy and the United States of America for general commercialization and use of C15:0 as a supplement, food or beverage ingredient, and pharmaceutical (U.S. Patent No. 11,116,740). In addition, our founders’ extensive science has enabled the fatty15 team to have exclusive patent rights across numerous specific indications, including (but not limited to) use of C15:0 to support:

  • Metabolic health, including but not limited to addressing conditions relevant to glucose control, type 2 diabetes, and metabolic syndrome
  • Heart health, including but not limited to addressing conditions relevant to dyslipidemia, vascular disease, and inflammation
  • Liver health, including but not limited to addressing conditions relevant to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
  • Immune health, including but not limited to lowering conditions relevant to inflammation
  • Red blood cell health, including but not limited to addressing conditions relevant to anemia and iron dysmetabolic syndrome
  • Healthy aging, including but not limited to addressing conditions relevant to age-related conditions and longevity
  • Brain health
  • Improved sleep
  • Controlled appetite
  • Improved mood, including but not limited to addressing conditions relevant to anxiety, depression, and drug addiction
  • and more...

Beyond the general use of C15:0 and the many science-backed indications, our founders’ diligent science has also enabled Seraphina to have exclusive rights from the U.S. Navy and the United States of America around C15:0 formulations, oral dosing, and targeted C15:0 body levels. A list of many of the exclusively licensed patents to Seraphina Therapeutics and fatty15, including U.S. and international patents, is available below.

In summary, any entity other than fatty15 that is marketing or selling C15:0 as a supplement in the U.S. or any other covered countries, is infringing on patents from the U.S. Navy and the United States of America.

patent

US11116740

patent

US10449170

patent

US10449171

patent

US9662306

patent

US10022347

patent

US10,238,618 B2

patent

US10,307,388 B2

patent

US18/168,382

patent

US18/170,379

patent

US17/086,198

patent

US18/447,059

patent

AU2019271067

patent

AU2021329343

patent

AU2021329909

patent

CA3099561

patent

CA3189188

patent

CA3039591

patent

CA3039594

patent

EU3562480

patent

EU2159078.4

patent

EU21859083.4

patent

EU19804528.8

patent

EU18870336.7

patent

EU21189054.6

patent

EU23169882

patent

FR3562841

patent

DE602018022346

patent

IT502021000097403

patent

JP7064879

patent

JP7037367

patent

JP7266366

patent

JP2023-512165

patent

JP2020-564401

patent

JP2023-067618

patent

MX378434

patent

MX385604

patent

MX376781

patent

MX2020/011533

patent

ES3562841

patent

GB3562841